



Wed 13th January 2021

Today's issue of PD

Pharmacy Daily today features three pages of news.

Naloxone pilot extended to Jun

THE Government's Take Home Naloxone (THN) Pilot scheme will run for an additional four months, according to an update from the Pharmacy Programs Administrator last week.

The program launched just over 12 months ago (PD 26 Nov 2019) and will now extend through to 30 Jun 2021.

Under the initiative naloxone will continue to be available for free and without a prescription to people who may experience or witness an opioid overdose in NSW, SA and WA.

"The extension will also allow for the continued collection of important evaluation data," the update noted.

EXHIBITORS and delegates attending the 2021 Australian Pharmacy Professional Conference (APP) who spend a minimum of \$20,000, will be eligible for a 50% rebate through Austrade's \$50 million Business Events Grants program.

Announcing the successful application for access to the funding, APP Convenor and former Pharmacy Guild of Australia National President, Kos Sclavos, urged attendees to review their costs and complete the online submission form to receive refunds.

"This is a great initiative by the Federal Government to encourage more delegates and exhibitors to attend conferences in 2021," he said.

"As the funding comes from a national pool and it's a first in, best dressed scenario, we encourage anyone interested in accessing this grant to do so now so they don't miss out."



Sclavos noted that APP, which will run from 20 to 23 May at the Gold Coast Convention and Exhibition Centre, will be operated as a COVID safe event, which will be submitted to the Queensland Government Public Health Unit for approval.

To date APP and the Guild's 2021 Tasmanian Pharmacy Conference, which is scheduled to take place on 20 and 21 Feb in Hobart, have been the only pharmacy events to be listed on the initial schedule of 102 approved business events.

Austrade said it would contact

organisers of events who have made expressions of interest on behalf of more than 700 conferences and exhibitions by the end of Jan, noting those that do not meet program eligibility will be encouraged to request feedback to adjust their applications and resubmit before the offical closing date of 26 Feb.

However, Austrade warned the deadline for expressions of interest "may close earlier to manage demand on the program or if all program funds are committed".



ready to change with it. We've always been focused on innovation and delivering best-in-class systems that empower our franchisees.

But don't just take our word for it. The Pharmacy Guild of Australia named Wizard Pharmacy Kalgoorlie Central as the WINNER of the 2020 POTY Excellence in Professional Innovation category.

to continue to best serve customers, especially in today's changing world. Wizard provides the systems and support that allows us to continually improve our business and how we serve our customers. ELISE WHEADON



WINNER EXCELLENCE IN PROFESSIONAL INNOVATION

CONTACT | Lyndon Dyson-0417 937 299 | wizardpharmacy.com.au/joinus

Pharmacy Daily

t 1300 799 220

w www.pharmacydaily.com.au

WIZARD PHARMACY FR. JOINED 2008



keep dreaming...

Travel & Cruise

Wed 13th January 2021

Guild backs Kelly's AZ COVAX stance

AUSTRALIANS are being urged to hold off on drawing conclusions about the efficacy of the AstraZeneca/Oxford University COVID-19 vaccine, based on incomplete data, by the Commonwealth's Chief Medical Officer (CMO), Paul Kelly.

In an interview with *Nine's Today* program this morning, Kelly expressed dismay at reports published in *The Age* and *Sydney Morning Herald*, that the Australasian Virology Society was calling for an immediate pause in plans to rollout the vaccine, which is set to form the bulk of Australia's COVID-19 immunisation prorgam.

"I'm concerned once controversy is opened up and people make comments based on interim results from a Phase III trial," he said.

"Once that sort of conversation starts, of course people will be wondering about if it's the right decision, [but] we'll be guided by the actual medical advice.

"We will be guided on the

Therapeutic Goods Administration (TGA) advice, they'll have all the information they need to make decisions about what vaccines are safe, what vaccines are effective and what vaccines are of high quality.

"[The AZ vaccine] is, on the evidence we have so far, a safe and effective vaccine, and we'll know more about that once the TGA has done all its work."

Pharmacy Guild of Australia Victorian Branch President, Anthony Tassone, backed the CMO's stance and urged the community to have confidence in the TGA's approval process.

"With the current locally acquired cases and overall active cases we have, Australia has the benefit of being able to take the time necessary through our independent medicines regulator the TGA, to evaluate all of the data from clinical trials and the early roll-out of international vaccination programs before a final approval is given to



training de titles au

administer to our citizens," he said.

"The Federal Government has also tried to diversify our vaccine portfolio with what they've purchased in order to not have 'all of our eggs in one basket'.

"The comments made by Chief Medical Officer Paul Kelly expressing caution by drawing conclusions on incomplete data are sensible.

"We should have confidence in the regulatory approval process to take its course in an environment of already time-compressed drug discovery, development and emergency administration and roll out overseas."

Make a quit plan

antiput manufactor of the second

SMOKERS looking to kick the habit in 2021 are being urged to embrace online tools including Quit's Make a Plan.

The smoking cessation support service's Director, Dr Sarah White, reported more than 33,000 people used the plan to quit in 2020.

White noted that while many people look to the New Year to make a fresh start and attempt to give up smoking, waiting to get back into a post-holiday routine can often be a better approach to successfully quitting.

"With holiday triggers and temptations out of the way, a fresh headspace and (hopefully) more energy, mid-Jan is a great time to stop smoking," she said.

White added that research showed combining support services with nicotine replacement therapies was the most effective way to quit.



Want face-to-face access to buyers at Australia's largest pharmacy trade exhibition?

<image><text>

Limited stands are available at the Australian Pharmacy Professional Conference & Trade Exhibition (APP2021).

Exhibitors are eligible to apply for Business Events Grants Program funding to cover 50% of costs. For further details or to book, call 07 3144 3629 or email events@qldguild.org.au

www.appconference.com



Pharmacy Daily e in

The Pharmacy

Guild of Australia

e info@pharmacydaily.com.au

t 1300 799 220





Wed 13th January 2021

Dispensary Corner

A STRANGE attempt by a Canadian couple to flout coronavirus restrictions has been nipped in the bud by officials enforcing a new curfew in Quebec, according to a report in the *La Tribune* newspaper.

New rules require citizens to stay indoors between 8pm and 5am - unless they are walking their dogs.

Police spotted the pair outside in the suburb of Sherbrooke after the curfew had come into effect, but noted that oddly the woman was holding a leash attached to the man's neck.

She insisted that since her husband was a "dog" they were complying with the rules.

However officers did not agree and issued each of them a CAD\$1,000 fine.

AND on a similar topic (sort of), comes a report from Korea where a startup has launched an artificial intelligence-powered dog collar which claims to help canines communicate with their owners.

The special Petpuls collar works in conjunction with a smartphone application to analyse barks, with the inventors saying it is able to tell pet-lovers if their fur babies are happy, relaxed, anxious, angry or sad.

The gadget, currently being sold online for US\$99, is based on analysis of thousands of barks from 50 different breeds, with testing by the Seoul National University finding it had a 90% average accuracy rate for emotional recognition. **RESEARCHERS** from Monash University may have discovered a method to revert antibiotic resistance in danagerous superbugs, using bacteriophages.

Data published in *Nature Microbiology*, showed phages could be used to kill *Acinetobacter baumannii*, which the authors said was responsible for up to 20% of infections in intensive care units. Lead author from the Monash

University School of Biological Science, Dr Fernando Gordillo Altamirano, noted phages are viruses which "only kill bacteria... but cannot harm humans".

The authors found that A. baumannii developed resistance to the phages, but in doing so lost their resistance to antibiotics.

"A. baumannii produces a capsule, a viscous and sticky outer layer that protects it and stops the entry of antibiotics," Gordillo Altamirano said.

THE International

(FIP) has appointed 20

Pharmaceutical Federation

pharmacists from across the

globe to the new One FIP Data

and Intelligence Commission,

the FIP Global Pharmaceutical

comprehensive and respected

Members include Monash

from Europe, the USA, Africa,

The new Commission will

hold its inaugural meeting this

month, with the aim of ensuring

Asia and the Americas.

University's John Jackson, along

with other eminent pharmacists

Observatory (GPO) as "the most

which aims to support the

organisation in developing

source of pharmacy data".

"Our phages use that same capsule as their port of entry to infect the bacterial cell.

Phages revert antibiotic resistance

"In an effort to escape from the phages, *A. baumannii* stops producing its capsule; and that's when we can hit it with the antibiotics it used to resist."

The study showed resensitisation

that the GPO has "regional

'The GPO is fundamental to

delivering the wider FIP vision of

a world where everyone benefits

quality and affordable medicines

from access to safe, effective,

and health technologies, as

well as from pharmaceutical

pharmacists," according to an

aligned with FIP's workforce

the identification of trends

to enable decision making

development goals, including

on deployment and supply of

pharmaceutical workforces.

FIP statement issued last week.

care services provided by

The GPO initiative is

applicability and sectoral

relevance".

to at least seven different antibiotics, Monash University School of Biological Science Group Leader, Dr Jeremy Barr said.

"This greatly expands the resources to treat *A. baumannii* infections," Dr Barr said.

"We're making this superbug a lot less scary."

Feeding forum

UK HEALTH Minister, Nadine Dorries, has launched a "Safer Medicines in Pregnancy and Breastfeeding Consortium", with 16 organisations gathering under a "common pledge to meet the information needs of pregnant and breastfeeding women and healthcare professionals through accessible, clear and consistent advice".

The group spans the NHS and regulators plus key charitable and health organisations.

Dorries said more info was vital for the over 50% of expectant mums who will need to take some sort of medicine while pregnant.

EDITORIAL Editor in Chief and Publis Editor – Nicholas O'Donog

www.pharmacydaily.com.au Pharmacy Daily is part of the Business Publishing Group family ir

of publications. *Pharmacy Daily* is Australia's favourite pharmacy industry publication. Editor in Chief and Publisher – Bruce Piper Editor – Nicholas O'Donoghue Contributors – Adam Bishop, Myles Stedman info@pharmacydaily.com.au ADVERTISING AND MARKETING Sean Harrigan, Hoda Alzubaidi advertising@pharmacydaily.com.au

FIP launches data commission

BUSINESS MANAGER Jenny Piper accounts@pharmacydaily.com.au Suite 1, Level 2, 64 Talavera Rd Macquarie Park NSW 2113 Australia PO Box 1010 Epping NSW 1710 Australia Tel: 1300 799 220 (+61 2 8007 6760)

Sign up free at www.pharmacydaily.com.au

Travel Daily CRUISE Travel & Cruise Weekly travelBulletin

Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Bruce Piper.

Pharmacy Daily

Pharmacy

e info@pharmacydaily.com.au

t 1300 799 220

w www.pharmacydaily.com.au